Enes Güncüm

Enes Güncüm

Auto-generated profile, based on publicly available information

Enes Güncüm

Kirikkale Universitesi

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 May 2018 in Artificial Cells, Nanomedicine, and Biotechnology
Verified
Journal Article
Closed access
EGEnes Güncüm
Enes Güncüm
NINuran Işıklan
Nuran Işıklan
CACeren Anlas
Ceren Anlas
NÜNilgün Ünal
Nilgün Ünal
EBElif Bulut
Elif Bulut
TBTülay Bakırel
Tülay Bakırel
In this study, amoxicillin (AMO)-loaded poly(vinyl alcohol)/sodium alginate (PVA/NaAlg) nanoparticles were prepared as a polymer-based controlled release system. The physicochemical properties of the obtained nanoparticles were investigated by XRD, DSC/TGA, particle size analyses and zeta potential measurements. The average particle sizes were in the range from 336.3 ± 25.66 to 558.3 ± 31.39 nm with negative zeta potential values from −41.86 ± 0.55 to −47.3 ± 2.76 mV. The influences of PVA/NaAlg ratio, span 80 concentration, exposure time to glutaraldehyde (GA) and the drug/polymer ratio on AMO release profiles were evaluated. In vitro drug release studies showed a controlled and pH dependent AMO release with an initial burst effect. XRD patterns and DSC thermograms of AMO-loaded nanoparticles revealed that the drug in the nanoparticles was in amorphous form, which was more stable than the crystalline form. The antibacterial activity of the optimal formulation was also investigated. The minimum inhibitory concentration (MIC) values of this formulation had the comparable antibacterial activity with that of pure AMO. These results indicate that the developed nanoparticles could be a promising candidate drug delivery system for AMO.

31 March 2018 in Journal of Veterinary Pharmacology and Therapeutics
Verified
Journal Article
Closed access
PDF file
EGE. Güncüm
E. Güncüm
TBT. Bakırel
T. Bakırel
CACeren Anlas
Ceren Anlas
HEH. Ekici
H. Ekici
NIN. Işıklan
N. Işıklan

14 July 2022 in Journal of Veterinary Science
Verified
Journal Article
Open access
PDF file
ASAtaman Bilge Sari
Ataman Bilge Sari
YGYigit Gunes
Yigit Gunes
CACeren Anlas
Ceren Anlas
FUFulya Ustun-Alkan
Fulya Ustun-Alkan
EGEnes Guncum
Enes Guncum
TBTulay Bakirel
Tulay Bakirel
Sari AB, et al. J Vet Sci. 2022 Jul;23(5):e64. https://doi.org/10.4142/jvs.22048

16 February 2023 in Journal of Biomaterials Science, Polymer Edition
Verified
Journal Article
Closed access
EGEnes Güncüm
Enes Güncüm
NINuran Işıklan
Nuran Işıklan
CACeren Anlaş
Ceren Anlaş
EBElif Bulut
Elif Bulut
TBTülay Bakırel
Tülay Bakırel
In this study, nanoparticles of amoxicillin (AMX) were prepared using chitosan (CHI) and polyethylene glycol (PEG). The physicochemical properties of the particles were investigated by FT-IR, DSC, SEM, and zeta potential analyses. The nanoparticles showed a spherical shape, and the average size of formulations was within the range of 696.20 ± 24.86 - 359.53 ± 7.41 nm. Zeta potential data demonstrated that the formulations had positive surface charges with a zeta potential range of 21.38 ± 2.28 - 7.73 ± 1.66 mV. FTIR analysis showed that the drug was successfully entrapped in the nanoparticles. DSC results suggested that the drug was present in amorphous form in the polymer matrix. In vitro release studies demonstrated that the release pattern consisted of two phases, with an initial burst release followed by a controlled and sustained release. The MTT assay results on mouse fibroblast cell line indicated that the prepared formulations did not affect the viability of the cells. In the in vitro antibacterial activity test, it was found that the drug-loaded nanoparticles have AMX-equivalent antibacterial activity against E. coli, and S. aureus. These findings revealed that the obtained nanoparticles might be a promising and safe nanocarrier system for efficient delivery of AMX. Graphical Abstract

1 September 2021 in Toxicology Letters
Verified
Journal Article
Closed access
EGEnes Guncum
Enes Guncum
TBTulay Bakirel
Tulay Bakirel
CACeren Anlas
Ceren Anlas
NINuran Isiklan
Nuran Isiklan
FUFulya Ustun-Alkan
Fulya Ustun-Alkan
AAAhmet Aydın
Ahmet Aydın

14 March 2024 in Andrology
Verified
Journal Article
Open access
YŞYaşar Şahin
Yaşar Şahin
EÜEvren Üstüner
Evren Üstüner
HTHidayet Tutun
Hidayet Tutun
EYEbru Yildirim
Ebru Yildirim
OEOğuz Eroğlu
Oğuz Eroğlu
ABAhmet Bilgehan Bilge
Ahmet Bilgehan Bilge
Background and objective: This study aimed to assess the protective ability of edaravone on testicular torsion–detorsion injury in rats.Methods: Eighteen adult male Sprague–Dawley rats were randomly divided into three groups: Sham group (control, n = 6); testicular torsion/detorsion (T/D group, n = 6) and T/D+edaravone (T/D+E group, n = 6). The spermatic cords of rats of the T/D group and the T/D+E group were rotated 720° in a clockwise direction and maintained for 120 min in this torsion position. Around 90 min after the torsion, edaravone at a dose of 10 mg/kg dissolved in saline was administered IP to the T/D+E group. The testicle was counter‐rotated to its normal position to allow reperfusion for 4 h. Left testes of each animal were excised 240 min after beginning of reperfusion. Oxidative stress markers (TAS, TOS, SOD, and MDA) and apoptotic pathways (Caspase 3, Caspase 8, Caspase 9, Bcl‐2, and Bax,) were assessed by ELISA methods. Also, testicles were subjected to the histopathologic and ultrasound examinations.Results: Ultrasound imaging showed that edaravone reduced the surface area and increased vascularization in testicles with T/D (p < 0.0001, p < 0.05, respectively). Edaravone pretreatment markedly decreased the levels of MDA, TOS, Bcl‐2, Bax, Caspase 3, Caspase 8, and Caspase 9 (p < 0.0001). Also, it increased significantly TAS levels (p < 0.0001) and reduced insignificantly SOD activity. Histopathologic examinations demonstrated that edaravone significantly attenuated the histological damage caused by T/D in testicles.Conclusion: Taken together, the findings indicate that pretreatment of edaravone has protective effect against testicular T/D injury.